44th week of 2011 patent applcation highlights part 36 |
Patent application number | Title | Published |
20110268736 | METHOD FOR TREATING CONGENITAL MYOPATHY - The invention relates to methods and compositions for therapy for congenital myopathies. | 2011-11-03 |
20110268737 | HLA-G PROTEINS AND PHARMACEUTICAL USES THEREOF - The present invention relates to novel proteins and pharmaceutical uses thereof. The invention more specifically relates to novel fusion proteins comprising a domain of an HLA-G antigen fused to an Fc domain of an immunoglobulin. The invention also relates to methods of producing such polypeptides, pharmaceutical compositions comprising the same, as well as their uses for treating various diseases including organ/tissue rejection. | 2011-11-03 |
20110268738 | Antibodies Against Hmgb1 and Fragments Thereof - In various embodiments, the present invention is drawn to antibodies or antigen-binding fragments thereof that bind to particular fragments of HMGB1, methods of treating a condition in a subject characterized by activation of an inflammatory cytokine cascade, methods of detecting and/or identifying an agent that binds to an HMGB1 polypeptide or fragment thereof, and methods of detecting HMGB1 in a sample. | 2011-11-03 |
20110268739 | Human binding molecules having killing activity against enterococci and uses thereof - Described are human binding molecules specifically binding to enterococci and having killing activity against enterococci, nucleic acid molecules encoding the human binding molecules, compositions comprising the human binding molecules and methods of identifying or producing the human binding molecules. The human binding molecules can be used in the diagnosis, prophylaxis, and/or treatment of a condition resulting from | 2011-11-03 |
20110268740 | FULLY HUMAN INFLUENZA M2 SPECIFIC ANTIBODIES - The present invention relates to human antibodies, preferably to fully human antibodies, which are specifically binding to influenza M2e antigen. The invention further relates to individual light- and/or heavy chains of such antibodies, to nucleic acids encoding said antibodies or their light- and/or heavy chain, and to expression vectors for the expression of said anti-bodies. Furthermore, the invention relates to the use of said antibodies in the treatment and/or prevention of influenza A virus infection, preferably in humans. | 2011-11-03 |
20110268741 | Immunotherapy for Contact Dermatitis Using Co-Signal Regulation - Compounds, compositions and methods for immunotherapy in contact dermatitis. Compounds and compositions (e.g. monoclonal antibodies) that stimulate the LAIR-1 expression pathway in LAIR-1 expressing immune cells and are useful for preventing or treating contact dermatitis are provided. | 2011-11-03 |
20110268742 | PCTP MODULATORS IN THE TREATMENT OF ACNE, OF SEBORRHOEIC DERMATITIS OR OF HYPERSEBORRHOEA - An in vitro or in vivo method for screening for candidate compounds for the preventive or curative treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea, includes determining the ability of a compound to modulate the expression or the activity of the phosphatidylcholine transfer protein (PCTP), and also utilizes modulators of the expression or of the activity of this protein, for the treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea; methods for the in vitro diagnosis of or in vitro prognosis for these pathologies are also featured. | 2011-11-03 |
20110268743 | PROBIOTICS, SECRETORY IgA AND INFLAMMATION - The present invention relates generally to the field of nutrition, health and wellness. In particular the present invention relates to probiotics and ways to increase their effectiveness. One embodiment of the present invention relates to a combination of probiotics with SIgA and possible uses of this combination. For example a use of a composition comprising SIgA and at least one probiotic for the preparation of a product to treat or prevent inflammation is disclosed. | 2011-11-03 |
20110268744 | Method of Diagnosis of Infection by Mycobacteria and Reagents Therefor - The present invention provides isolated | 2011-11-03 |
20110268745 | Antibodies Against Tissue Factor Pathway Inhibitor (TFPI) - The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce clotting time in (a) human FVIII-deficient plasma and/or (b) human whole blood. Such antibodies have utility in the treatment of bleeding disorders and in the stimulation of blood clotting. | 2011-11-03 |
20110268746 | HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF - The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease. | 2011-11-03 |
20110268747 | STXBP1 AS PSYCHIATRIC BIOMARKER IN MURINE MODEL SYSTEM AND THEIR USES - A non-human transgenic animal having a polynucleotide encoding an STXBP1 polypeptide, which polynucleotide is operably linked to a promoter, wherein said transgenic animal has greater than wild-type expression of the STXBP1 polypeptide in at least one brain region, as well as related vectors, methods of producing transgenic animals, in vitro and in vivo screening methods for potential therapeutic agents, and methods for treating and diagnosing neuropsychiatric illness are disclosed. | 2011-11-03 |
20110268748 | NURR-1 Interacting Protein (NuIP) - Provided herein are methods of promoting the activity of Nurr1 in a cell comprising contacting the cell with NuIP or an analog or fragment thereof. Also provided are methods of treating or preventing a condition associated with reduced dopaminergic function in a subject, comprising administering to the subject NuIP or an analog or fragment thereof. Methods of inhibiting the activity of Nurr1 in a cell comprising contacting the cell with a NuIP inhibitor are provided. Methods of screening for agents that modulate the interaction of Nurr1 and NuIP are also provided. | 2011-11-03 |
20110268749 | TREATMENT OF CANCER VIA TARGETING OF IL-13 RECEPTOR-ALPHA2 - Disclosed herein are compositions and methods for treating or preventing cancer involving the use of a TNF-alpha antagonist, an IL-13Rα | 2011-11-03 |
20110268750 | CHIMERIC POLYNUCLEOTIDES AND POLYPEPTIDES ENABLING SECRETION OF A POLYPEPTIDE OF INTEREST IN ASSOCIATION WITH EXOSOMES AND USE THEREOF FOR THE PRODUCTION OF IMMUNOGENIC COMPOSITIONS - The present invention concerns a chimeric polypeptide comprising several polypeptide domains, which is capable of being secreted in association with membrane vesicles and in particular exosomes. | 2011-11-03 |
20110268751 | Weekly Dosing Regimens for Anti-CD30 VC-PAB-MMAE Antibody Drug-Conjugates - Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30 antibody unit, S is a sulfur atom of the antibody, A—is a Stretcher unit, and p is from about 3 to about 5. | 2011-11-03 |
20110268752 | Inducible Regulatory T-Cell Generation for Hematopoietic Transplants - The present invention provides methods and compositions for converting non-Tregs into Tregs. The converted Tregs are referred to as inducible Tregs (iTregs). The iTregs are useful for preventing, suppressing, blocking or inhibiting an immune response. For example the iTregs are useful for preventing rejection of a transplanted tissue in a human or other animal host, or protecting against graft vs host disease. The iTregs can also be used to treat autoimmune diseases. | 2011-11-03 |
20110268753 | PROCESS FOR REGULATING IMMUNE RESPONSE - The discovery of FcγRIIc expression on B-cells allows several new methods of prediction or regulation of immune responses. A process of altering an immune response in a subject is provided by altering the expression level or activity of FcγRIIc on a cell. The relative ratio of activating FcγRIIc to inhibitory FcγRIIb levels in an immune cell allows prediction of the presence or absence of immune disease or abnormality such as rheumatoid arthritis or systemic lupus erythematosus. Inventive processes are provided whereby the relative levels of activating to inhibitory receptor expression in a subject is compared to an established inventive classification system to predict an immune response to a therapeutic, the presence or absence of disease, or the magnitude, duration, or timing of an immune response in the subject. | 2011-11-03 |
20110268754 | IMMUNOTHERAPY WITH IN VITRO-SELECTED ANTIGEN-SPECIFIC LYMPHOCYTES AFTER NONMYELOABLATIVE LYMPHODEPLETING CHEMOTHERAPY - A method of promoting the regression of a cancer in a mammal comprising: (i) administering to the mammal nonmyeloablative lymphodepleting chemotherapy, and (ii) subsequently administering: (a) autologous T-cells, which have been previously isolated, selected for highly avid recognition of an antigen of the cancer, the regression of which is to be promoted, and rapidly expanded in vitro only once, and, either concomitantly with the autologous T-cells or subsequently to the autologous T-cells, by the same route or a different route, a T-cell growth factor that promotes the growth and activation of the autologous T-cells, or (b) autologous T-cells, which have been previously isolated, selected for highly avid recognition of an antigen of the cancer, the regression of which is to be promoted, modified to express a T-cell growth factor that promotes the growth and activation of the autologous T-cells, and rapidly expanded in vitro only once, whereupon the regression of the cancer in the mammal is promoted. | 2011-11-03 |
20110268755 | Survivin Peptides For Autoimmune Therapies - Compositions and methods for stimulating an immune response against cells that express survivin are provided. The method is suitable for prophylaxis and/or therapy of autoimmune disorders. The method involves administering to an individual a composition that contains a survivin peptide mimic that has a cysteine to methionine alteration at amino acid position 57 of wild type survivin. Fragments of the peptides can also be used. | 2011-11-03 |
20110268756 | MODIFIED AMYLOID BETA PEPTIDE - An object of the invention is to provide a peptide based on a sequence of an amyloid β peptide that may allow for induction of enhanced immune response and is safe and efficacious for prophylaxis and treatment of Alzheimer disease. An amyloid β peptide or a portion thereof with addition or insertion of cysteine or a cysteine analogue, and a method for enhancing immune response to amyloid β using said peptide, a medicament for prophylaxis and treatment of Alzheimer disease using said amyloid β peptide that induces an enhanced immune response, and a DNA vaccine comprising a gene coding for an amyloid β peptide or a sequence derived from an amyloid β peptide with addition or insertion of cysteine or a cysteine analogue, as expected to be similarly efficacious. | 2011-11-03 |
20110268757 | USE OF PHENOL-SOLUBLE MODULINS FOR VACCINE DEVELOPMENT - The invention relates to methods for increasing immunogenicity of an antigenic peptide by means of its covalent coupling to a modulin derived peptide (PSM, phenol soluble modulin). In particular, the binding of PSMα, PSMγ and PSMδ peptides to an antigen (from a pathogen or a tumor associated protein) increases the capacity of the antigen to activate an immune response in vivo. Thus, the PSMα, PSMγ and PSMδ peptides bound to these antigens may be used in the development of vaccines for preventing or treating infectious diseases or cancer | 2011-11-03 |
20110268758 | TUBERCULOSIS ANTIGEN DETECTION ASSAYS AND VACCINES - The present invention relates to isolated Tuberculosis (TB) antigens that are useful in therapeutic and vaccine compositions for stimulating a TB specific immunological response. The identified antigens are also useful in diagnostic assays to determine the presence of active TB in an individual. Accordingly, the present invention includes polypeptide molecules, nucleic acid molecules, vaccine compositions, diagnostic assays, and methods of diagnosis and monitoring treatment related to these TB antigens. | 2011-11-03 |
20110268759 | NOVEL ANTI-STRETCH MARK ACTIVE AGENT, AND COMPOSITIONS CONTAINING SAME - The invention relates to a method for the cosmetic prevention and/or treatment of stretch marks on the skin, characterised in that the method comprises administering a composition containing arabinogalactan as an active principle to a person that may develop or has stretch marks. Said cosmetic composition can be administered in a topical or oral manner. | 2011-11-03 |
20110268760 | SALMONELLA VECTORED VACCINES AGAINST CHLAMYDIA AND METHODS OF USE - The invention provides an attenuated Salmonella vaccine vector comprising one or more heterologous polynucleotides that encode immunogenic Chlamydial peptides. In one embodiment, the attenuated Salmonella vaccine vector comprises aroC and ssaV attenuating mutations. The heterologous polynucleotides encoding the immunogenic Chlamydial peptides can be under the control of an inducible promoter such as a Salmonella ssaG promoter. In one embodiment of the invention, the immunogenic Chlamydial peptide is a PmpG peptide, for instance, a CT110, CT84 or CT40 peptide. | 2011-11-03 |
20110268761 | Effective Sensitizing Dose of a Gelled Immunomodulating Topical Composition - The present invention relates to compositions and methods of treating warts and other human papilloma virus (HPV) skin infections. The present invention relates to compositions and methods of treating skin cancer. | 2011-11-03 |
20110268762 | IMMUNIZATION OF AVIANS BY MUCOSAL ADMINISTRATION OF NON-REPLICATING VECTORED VACCINES - The present invention relates generally to the fields of immunology and vaccine technology. More specifically, the invention relates to mucosal administration via aerosol spray to avians of immunogenic and vaccine compositions, including those comprising recombinant human adenovirus vectors for delivery of genes encoding avian immunogens or antigens, such as genes encoding avian influenza virus. The invention also provides methods and apparatus for use in such administration. | 2011-11-03 |
20110268763 | POLYNUCLEOTIDES THAT STIMULATE NEUTROPHILS - The polynucleotides of the present invention are complementary to the Initiation Sites of microbes. Invading organisms, sensing the pH and nutrient deprivation of a physiologic environment quickly release these nucleotides triggering rapid growth and mutation—attributes to successfully establishing a nidus of infection. They also stimulate neutrophil functions. Accordingly, the nucleotides, compositions and methods of the present invention may be used to enhance, restore or stimulate an immune response or system of an animal, e.g. to prevent an infection caused by a microorganism, ameliorate an infection caused by a microorganism, or kill an invading microorganism that causes infection or re-establish balance to an immune system. In particular, the polynucleotides, compositions and methods of the present invention may be used to treat or prevent bacterial infections and auto-immune diseases in a mammal in need thereof. | 2011-11-03 |
20110268764 | IMMUNE RESPONSE INDUCING PREPARATIONS - The present invention provides a pharmaceutical composition with an adjuvant based on an apathogenic virus, together with an antigen. The adjuvant has a natural or through genetical engineering no, reduced or altered expression of an endogenous interferon antagonist or endogenous immune suppressor. | 2011-11-03 |
20110268765 | Injectable Botulinum Toxin Formulations - This invention provides novel injectable compositions comprising botulinum toxin that may be administered to a subject for various therapeutic, aesthetic and/or cosmetic purposes. The injectable compositions contemplated by the invention exhibit one or more advantages over conventional botulinum toxin formulations, including reduced antigenicity, a reduced tendency to undergo unwanted localized diffusion following injection, increased duration of clinical efficacy or enhanced potency relative, faster onset of clinical efficacy, and/or improved stability. | 2011-11-03 |
20110268766 | Engineered Cells Expressing Multiple Immunomodulators And Uses Thereof - This invention relates to the field of therapeutics. Most specifically invention provides methods of generating in vitro engineered immune cells conditionally expressing interleukin-12 (IL-12) and one or more immunomodulators under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals. | 2011-11-03 |
20110268767 | USE OF ALLOGENEIC CELL LINES TO LOAD ANTIGEN-PRESENTING CELLS TO ELICIT OR ELIMINATE IMMUNE RESPONSES - Novel antigen-presenting cells, including but not limited to dendritic cells, that are loaded with antigens from dead or dying cells including allogenic cell lines, and the methods for making such antigen-presenting cells are described. These loaded antigen-presenting cells induce therapeutic immune responses in humans. Such loaded antigen-presenting cells are useful in the management of cancer. Antigen-loaded dendritic cells prepared as described here can prime naïve T cells to differentiate into effector cells able to recognize multiple and/or shared tumor antigens that are expressed either on the tumor cells that are used to load the dendritic cells and/or on other tumor cells. The cytotoxic T cells generated by exposure to antigen-loaded dendritic cells prepared as described here can be used in adoptive therapy. This induction of responses against multiple antigens shared between different cells, for instance tumor cells, as described here is important as it leads to broad immune responses. | 2011-11-03 |
20110268768 | Compositions and Methods for Treating Atherosclerosis - Peptides and mimetics of selected domains of mammalian serum amyloid A isoform 2.1 (SAA2.1) and compounds and compositions thereof are provided that enhance the effect on macrophage cholesterol ester hydrolase activity and/or inhibit acyl CoA:cholesterol acyl transferase activity. Methods of using these compositions in the treatment and/or prevention of atherosclerosis as well as coronary heart disease and cardiovascular disease are also provided. | 2011-11-03 |
20110268769 | DRUG DELIVERY VEHICLE FOR CANCER THERAPY, PROCESS FOR PRODUCING THE SAME, AND PHARMACEUTICAL PREPARATION USING THE SAME - The invention provides a vehicle that can deliver drugs specifically to the body and a pharmaceutical preparation using the same. Disclosed is a drug delivery vehicle for cancer therapy, comprising a cationized viral envelope vector, as well as a pharmaceutical preparation comprising a drug enclosed in the vehicle. The viral envelope vector is for example HVJ-E derived from a Sendai virus, and cationization can be conducted by binding hyaluronic acid-introduced cationized gelatin or ethylene glycol-introduced cationized gelatin with the viral envelope vector. The drug to be enclosed is a nucleic acid, a vector containing a nucleic acid sequence, a protein based drug or pharmaceutical with a low-molecular compound. | 2011-11-03 |
20110268770 | CHEWABLE GELLED EMULSIONS - An oral pharmaceutical composition in unit dose form, each unit dose comprising a statin within a unitary carrier body, said body comprising a soft, chewable, gelled oil-in-water emulsion, one or both of the oil phase and the water phase whereof comprises a physiologically tolerable omega-3 acid ester. | 2011-11-03 |
20110268771 | CHEWABLE GELLED EMULSIONS - An oral pharmaceutical composition in unit dose form, each unit dose comprising a lipophilic drug substance within a unitary carrier body, said body comprising a soft, chewable, gelled oil-in-water emulsion. | 2011-11-03 |
20110268772 | PHARMACEUTICAL COMPOSITION CONTAINING AN ANIONIC DRUG AND A PRODUCTION METHOD THEREOF - Disclosed are an anionic drug-containing pharmaceutical composition comprising: an anionic drug as an active ingredient; a cationic lipid; and an amphiphilic block copolymer, wherein the anionic drug forms a complex with the cationic lipid, and the complex is entrapped in the micelle structure of the amphiphilic block copolymer, and a method for preparing the same. The pharmaceutical composition may increase stability of the anionic drug in blood or in a body fluid, and it may enable intracellular delivery to improve efficacy of anionic drugs. | 2011-11-03 |
20110268773 | INCLUSION BODIES, BACTERIAL CELLS AND COMPOSITIONS CONTAINING THEM AND USES THEREOF - The present invention relates to an isolated inclusion body comprising a polypeptide, characterised in that such inclusion body is in particulate form. The present invention also refers to a bacterial cell comprising said inclusion body. The present invention additionally refers to a composition comprising said inclusion body and a eukaryotic cell. The present invention moreover refers to a composition comprising said inclusion body and animal or plant tissue. The present invention furthermore refers to the uses of said inclusion body as medicaments and cell-proliferation stimulators and tissue regenerators. | 2011-11-03 |
20110268774 | PREPARATION OF STEM CELLS WITH REPROGRAMMED CELL SIGNALLING, A METHOD OF PRODUCING THE PREPARATION AND A METHOD OF USE THEREOF - The invention is applied in the therapy of brain and spinal cord tumors, degenerative, hypoxic, ischemic diseases and traumatic injuries of the central nervous system (CNS) and other diseases of humans and animals. Object of invention is to provide target delivery of signaling substance to the pathological area of an organism, triggering in due time and long-time support of active signaling intercellular action of specific therapeutic character of a healthy and well controlled stem cell (SC) onto controlling system of defective cells. The preparation of SC with reprogrammed cell signaling comprises the basic preparation of SC, the membrane, and/or nucleus, and/or cytoplasm of which contains implanted protein or pharmaceutical able to regulate signaling pathways of SC and cells of pathological focus in a mammal organism, provisionally encapsulated in nanocontainers of less than 100 nm size, obtained from biodegradable material, intact for organelles and compartments of SC of the basic preparation. The material has a set biodegradation period in a mammal organism to provide programmed exit of protein or pharmaceutical in intra- or intercellular space thus reprogramming signal transduction of key genes in the desired therapeutic orientation of physiologic events in the cell cycle directly in the pathological area or tissue of an organism. | 2011-11-03 |
20110268775 | NANOPARTICLE PHARMACEUTICAL FORMULATIONS - The present invention is directed to methods of preparing nanoparticles of aqueous-insoluble compounds, particularly aqueous-insoluble bioactive (drug) compounds, and to compositions and medicaments obtained by these methods. These methods, compositions, and other inventive aspects of the present invention are based particularly on the use of bile acid compound(s) to prepare nanoparticles of aqueous-insoluble compounds. | 2011-11-03 |
20110268776 | PROGRAMMED-RELEASE, NANOSTRUCTURED BIOLOGICAL CONSTRUCT FOR STIMULATING CELLULAR ENGRAFTMENT FOR TISSUE REGENERATION - A biologically engineered construct comprising of a polymeric biomatrix, designed with a nanophase texture, and a therapeutic agent for the purpose of tissue regeneration and/or controlled delivery of regenerative factors and therapeutic substances after it is implanted into tissues, vessels, or luminal structures within the body. The therapeutic agent may be a therapeutic substance or a biological agent, such as antibodies, ligands, or living cells. The nanophase construct is designed to maximize lumen size, promote tissue remodeling, and ultimately make the implant more biologically compatible. The nano-textured polymeric biomatrix may comprise one or more layers containing therapeutic substances and/or beneficial biological agents for the purpose of controlled, physiological, differential substance/drug delivery into the luminal and abluminal surfaces of the vessel or lumen, and the attraction of target molecules/cells that will regenerate functional tissue. The topographic and biocompatible features of this layered biological construct provides an optimal environment for tissue regeneration along with a programmed-release, drug delivery system to improve physiological tolerance of the implant, and to maximize the cellular survival, migration, and integration within the implanted tissues. | 2011-11-03 |
20110268777 | Lotion Composition for Wet Wipes - A lotion composition for a skin cleaning wipe comprises a superwetter and a rheology modifier, adapted to provide an enhanced sensation of wetness with a reduced quantity of liquid. Complementary emollients, emulsifiers, and adjuncts and a method for increasing the wetness perception of a wet wipe are also described. | 2011-11-03 |
20110268778 | DELIVERY PARTICLES - The present application relates to encapsulated benefit agents, compositions comprising such encapsulated benefit agents and processes for making and using compositions comprising such encapsulated benefit agents. Such encapsulated benefit agents eliminate or minimize one or more of the drawbacks of current encapsulated benefit agents and thus provide formulators with additional perfume delivery opportunities. | 2011-11-03 |
20110268779 | GUM COMPOSITIONS - A chewing gum composition comprising porous silicon is described. | 2011-11-03 |
20110268780 | SOLID CORE MICROCAPSULAR COMPOSITIONS AND USES THEREOF - Provided are microcapsules containing a solid core including at least one essential oil mixed with a porous solid material, where this solid core is coated by at least one layer of a polyurea film and/or a polyurethane film or an amphipathic shell composed of a multivalent salt form of at least one alkanoic acid. Further provided are compositions including these microcapsules, and uses thereof in a variety of agricultural and environmental applications. | 2011-11-03 |
20110268781 | DRUG ELUTING COMPOSITE - The present invention relates to materials having therapeutic compositions releasably contained within the materials. The materials are configured to release therapeutic compositions at a desired rate. The present invention also relates to devices incorporating the materials. | 2011-11-03 |
20110268782 | POLYURETHANES FOR OSTEOIMPLANTS - Biological-based polyurethanes and methods of making the same. The polyurethanes are formed by reacting a biodegradable polyisocyanate (such as lysine diisocyanate) with an optionally hydroxylated biomolecule to form polyurethane. The polymers formed may be combined with ceramic and/or bone particles to form a composite, which may be used as an osteoimplant. | 2011-11-03 |
20110268783 | PARTIALLY MICROCELLULAR, SELECTIVELY HYDROPHILIC COMPOSITE CONSTRUCT FOR OCULAR DRUG DELIVERY - A partially microcellular, selectively hydrophilic composite as a self-standing construct or a component of a device for ocular delivery of at least one bioactive agent, the composite comprising a highly hydrophilic microcellular foam adjoined with a flexible hydrophobic barrier polymeric film. | 2011-11-03 |
20110268784 | CLAY-BASED HEMOSTATIC AGENTS AND DEVICES FOR THE DELIVERY THEREOF - A device for promoting the clotting of blood comprises a clay material in particle form and a receptacle for containing the clay material. At least a portion of the receptacle is defined by a mesh. Another device comprises a gauze substrate and a clay material disposed on the gauze substrate. Another device is a bandage comprising a substrate, a mesh mounted on the substrate, and particles of a clay material retained in the mesh. A hemostatic sponge comprises a substrate, a hemostatic material disposed on a first surface of the substrate, and a release agent disposed on a second surface of the substrate. The release agent is disposed on the wound-contacting surface of the substrate. When treating a bleeding wound, application of the hemostatic sponge causes at least a portion of the hemostatic material to come into contact with blood through the release agent and through the substrate. | 2011-11-03 |
20110268785 | Propynylaminoindan Transdermal Compositions - Propynylaminoindan (e.g., Rasagiline) transdermal compositions are provided. Aspects of the transdermal compositions include a matrix of the propynylaminoindan in a pressure sensitive adhesive comprising a carboxylated polymer. In some instances, the matrix further includes a cationic acrylic copolymer. Also provided are methods of using the transdermal compositions and kits containing the transdermal compositions. | 2011-11-03 |
20110268786 | PATCH PRODUCTION TECHNOLOGY - The invention relates to a transdermal, especially dopaminergic patch, comprising a release liner film, an active substance layer, and a carrier film, wherein the active substance layer is applied between the release liner film and the carrier film. The release liner film and/or the carrier film thereby comprise at least one separation edge brought about thermally, at least partially defining a peripheral edge of the patch. The invention further relates to a method for producing such a transdermal patch and to a tool for producing the patch according to the method according to the invention. Crystal growth in the active substance layer can be reliably prevented by the patch according to the invention. | 2011-11-03 |
20110268787 | Ocular compositions containing dioleoylphosphatidylglycerol and uses thereof - The present invention provides a method of treating a corneal disorder comprising administering to a patient in need thereof a composition containing pharmaceutically effective amount of dioleoylphosphatidylglycerol and/or palmitoyloleoylphosphatidylglycerol and a pharmaceutically acceptable carrier. | 2011-11-03 |
20110268788 | IMMUNOTHERAPEUTIC AGENT SUITABLE FOR THE PRIMARY PROPHYLAXIS OF TUBERCULOSIS - The present invention relates to the use of an immunotherapeutic agent having cell wall fragments of a virulent strain of | 2011-11-03 |
20110268789 | USE OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND PACAP ANALOGS AS ADJUNCTIVE TREATMENTS WITH ANTICANCER AGENTS - This invention relates to methods and compositions for the treatment, management or prevention of injuries to one or more of the organs of the body, such as the brain, heart, lung, kidneys, liver, and gastrointestinal tract, of humans or other mammals caused by one or more anticancer agents. The methods of this invention consist of the administration of an effective amount of one or more pituitary adenylate cyclase-activating polypeptide (PACAP)-like compounds, which includes native human PACAP38, native human PACAP27, native human vasoactive intestinal peptide (VIP), their agonists, analogs, fragments, and derivatives, with activities toward one or more of the PACAP/VIP receptors, including all of their various isoforms. This invention also provides pharmaceutical compositions of one or more PACAP-like compounds of the invention either alone or in combination with one or more other prophylactic/therapeutic agents useful for the treatment, management or prevention of injuries to the organs of the body of humans or other mammals undergoing cancer chemotherapy. Combination therapy with one or more PACAP-like compounds plus one or more anticancer agents can be used in the treatment of hematological cancers. | 2011-11-03 |
20110268790 | Snake Factor V and Methods of Use Thereof as a Procoagulant - Compositions and Methods for the treatment of coagulation disorders using Factor V variants are provided. Preferred disorders include hemophilia A and B. | 2011-11-03 |
20110268791 | POROUS NANOPARTICLE SUPPORTED LIPID BILAYER NANOSTRUCTURES - Various exemplary embodiments provide protocell nanostructures and methods for constructing and using the protocell nanostructures. In one embodiment, the protocell nanostructures can include a core-shell structure including a porous particle core surrounded by a shell of lipid bilayer(s). The protocell can be internalized in a bioactive cell. Various cargo components, for example, drugs, can be loaded in and released from the porous particle core of the protocell(s) and then delivered within the bioactive cell. | 2011-11-03 |
20110268792 | SURFACE ACTIVE PROTEINS AS EXCIPIENTS IN SOLID PHARMACEUTICAL FORMULATIONS - The invention relates to a use of surface active hydrophobins for applications in pharmaceutical technology, in particular as excipients for galenic use. Provided is a method for either admixture of hydrophobins to galenic compositions or for treating the surface of pharmaceutical forms with a hydrophobin-containing solution to modify the pharmaceutical properties of the galenic form. In a preferred embodiment of the invention hydrophobins are used to improve the properties of a pharmaceutical composition, e.g. to act as a surfactant or to increase resistance to disintegration of the galenic forms to achieve a retarded drug release. The galenic form to be modified by the use of surface active proteins as excipients can be capsules, tablets, pills, microparticles, vesicles, and suppositories, although further galenic forms are envisioned. The surface active proteins used for the purpose of present invention can either be isolated from their respective natural source or prepared by recombinant techniques and expression in a suitable host. | 2011-11-03 |
20110268793 | KITS AND METHODS FOR NUTRITION SUPPLEMENTATION - The present invention relates to methods of co-administration of various vitamin and mineral compositions, and in a specific embodiment, said methods comprise co-administering one composition comprising vitamin A, beta carotene, B-complex vitamins, vitamin C, vitamin D | 2011-11-03 |
20110268794 | METHODS AND MATERIALS FOR DELIVERING BILE ACIDS - This document relates to methods and materials for administering bile acid compounds to treat conditions associated with constipation. For example, formulations designed for the delayed-release of a bile acid compound (e.g., sodium chenodeoxycholate) to treat constipation are provided. | 2011-11-03 |
20110268795 | Compositions and methods for inducing satiety and treating non-insulin dependent diabetes mellitus, prediabetic symptoms, insulin resistance and related disease states and conditions - The invention provides methods of treatment that induce satiety in a subject for a period of at least around twenty-four hours by once-daily administration to the subject of a controlled release dosage form, wherein the dosage form is administered while the subject is in the fasted state and at a time of around six to around nine hours prior to the subject's next intended meal, and wherein the dosage form comprises a controlled release composition, which comprises an enterically-coated, ileum hormone-stimulating amount of a nutritional substance and releases the majority of the nutritional substance in vivo upon reaching the subject's ileum. The invention also provides a diagnostic tool for probing the health and disease state of the ileal hormones, excess or deficiencies. The invention provides a safe vehicle for targeted deliveries of chemical, pharmaceuticals, natural substances and nutrition to the ileum. The present invention also provides a method for treating noninsulin dependent diabetes mellitus, pre-diabetic symptoms, and insulin resistance, as well as a number of disease states and conditions including gastrointestinal disorders as otherwise described herein. | 2011-11-03 |
20110268796 | PHARMACEUTICAL FORMULATIONS USEFUL IN THE TREATMENT OF INSOMNIA - There is provided a formulation suitable for transmucosal administration comprising a short acting hypnotic drug, which formulation provides a measurable plasma concentration of drug within 10 minutes of administration. The formulation is capable of providing sleep on demand, and preferably comprises particles of drug, for example zolpidem or a pharmaceutically-acceptable salt thereof and a mucoadhesion promoting agent, such as sodium carboxymethylcellulose, which particles of drug and mucoadhesive are presented upon the surface of larger carrier particles. | 2011-11-03 |
20110268797 | MULTICOATED ALISKIREN FORMULATIONS - An oral pharmaceutical formulation of aliskiren, or a pharmaceutically acceptable salt or polymorph thereof, having at least two coating layers. | 2011-11-03 |
20110268798 | ORALLY DISNTEGRATING TABLETS FOR THE TREATMENT OF PAIN - An orally disintegrating tablet comprising acetylsalicylic acid, acetaminophen and caffeine and one or more pharmaceutically acceptable excipients. | 2011-11-03 |
20110268799 | ORAL CONTROLLED RELEASE DOSAGE FORM - A dosage form that provides a controlled release solid dosage form for the oral administration of a central nervous system stimulant, preferably methylphenidate hydrochloride. | 2011-11-03 |
20110268800 | Unsaturated fatty acids as thrombin inhibitors - A preparation having at least one unsaturated fatty acid and the use of at least one unsaturated fatty acid having a chain length of 18 or 20 carbon atoms and of plant drugs containing the unsaturated fatty acid as a free fatty acid or a fatty acid radical of a triglyceride. The fatty acid has a chain length of 18 carbon atoms which are provided with 1 to 3 double bonds and the fatty acid has a chain length of 20 carbon atoms which are provided with 1 to 4 double bonds. The double bond or one of the double bonds are located in position 9 or 11 of the carbon chain. The unsaturated fatty acid is supplied in the all-cis configuration. The at least one unsaturated fatty acid prevents and/or treats or is used for producing a preparation for preventing and/or treating thrombosis and thromboembolic diseases. | 2011-11-03 |
20110268801 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE - Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid. | 2011-11-03 |
20110268802 | DELIVERY PARTICLE - The present application relates to encapsulated benefit agents, compositions comprising such encapsulated benefit agents and processes for making and using compositions comprising such encapsulated benefit agents. Such encapsulated benefit agents eliminate or minimize one or more of the drawbacks of current encapsulated benefit agents and thus provide formulators with additional perfume delivery opportunities. | 2011-11-03 |
20110268803 | LUNG TARGETING DUAL DRUG DELIVERY SYSTEM - The American Cancer Society estimated that in 2009, 1,479,350 new cancer cases would be diagnosed in the United States of which 219,440 would be lung and bronchus related. The standard treatments for NSCLC include surgery, chemotherapy, radiation, laser and photodynamic therapy, all with various success rates depending on the stage of the cancer. National Cancer Institute assesses, however, that results of standard treatment are generally poor with only a 15 percent 5-year survival rate for combined cancer stages. Challenges facing the current chemotherapy drugs include excessive toxicity to healthy tissues and limited ability to prevent metastases. A dual drug delivery system described herein selectively targets the lung to deliver anti-cancer drugs and inhibit the formation of metastases. | 2011-11-03 |
20110268804 | TARGETING OF ANTIGEN PRESENTING CELLS WITH IMMUNONANOTHERAPEUTICS - The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides nanocarriers capable of stimulating an immune response in T cells and/or in B cells. The invention provides nanocarriers that comprise an immunofeature surface. The nanocarriers are capable of targeting antigen presenting cells when administered to a subject. The invention provides pharmaceutical compositions comprising nanocarriers. The present invention provides methods of designing, manufacturing, and using nanocarriers and pharmaceutical compositions thereof. | 2011-11-03 |
20110268805 | ADJUVANT INCORPORATION IN IMMUNONANOTHERAPEUTICS - The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides nanocarriers capable of stimulating an immune response in T cells and/or in B cells. The invention provides nanocarriers that comprise an immunofeature surface and an immunostimulatory moiety. In some embodiments, the immunostimulatory moiety is an adjuvant. The invention provides pharmaceutical compositions comprising inventive nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive nanocarriers and pharmaceutical compositions thereof. | 2011-11-03 |
20110268806 | ANTISOLVENT SOLIDIFICATION PROCESS - The present invention relates to a antisolvent solidification process wherein a liquid medium comprising at least one organic or inorganic compound which is to be solidified is forced through a membrane into one or more antisolvents, or wherein one or more antisolvents are forced through a membrane into a liquid medium comprising at least one organic or inorganic compound which is to be solidified, yielding a composition comprising solid particles comprising said organic and/or inorganic compound(s). | 2011-11-03 |
20110268807 | Biodegradable Microspheres and Methods of Use Thereof - The present invention provides biodegradable microspheres, compositions comprising a subject biodegradable microsphere, and methods of using a subject biodegradable microsphere for delivery of an agent to a site in an individual. | 2011-11-03 |
20110268808 | DUAL-RELEASE PHARMACEUTICAL SUSPENSION - Orally deliverable dual-release pharmaceutical suspensions, having a first portion comprising an immediate release form of the active in the solution form or granules or suspended form in the vehicle/medium preferably in the solution form and a second portion comprising a sustained-release form of active in the form of microgranules/microparticles suspended in the immediate release fraction of the solulabilised active agent which comprise a core and at least one coat suitable for liquid dosage forms for the administration of the active ingredients, wherein the core comprises at least one active agent(s) or its pharmaceutically acceptable salts, derivatives, isomers, polymorphs, solvates, hydrates, analogues, enantiomers, tautomeric forms or mixtures thereof; optionally at least one water insoluble, and optionally one or more pharmaceutically acceptable excipient(s); and at least one coat comprising at least one pH independent water-insoluble polymer(s) along with one or more pharmaceutically acceptable excipient(s). This coated microparticles and solution of the active agent in the vehicle ensures a dual release profile i.e. immediate release profile as well as predetermined sustained release profile of the active agent and also ensures maintenance of said release profile over time. The present invention can be administered either in the form of ready to use suspension or in the form of powder ready for reconstitution. Further, this invention provides process of preparation of such suspensions and method of using them. | 2011-11-03 |
20110268809 | Nicotine-Containing Pharmaceutical Compositions - A composition intended to be employed for therapeutic purposes incorporates a source of nicotine and at least one levulinate moiety. Representative forms of nicotine include free base (e.g., as a mixture of nicotine and microcrystalline cellulose), a nicotine salt (e.g., as nicotine bitartrate) or nicotine polacrilex. The levulinate moiety can have the form of an acid (e.g., levulinic acid), a levulinate salt (e.g., sodium levulinate), or an ester of levulinic acid (e.g., methyl levulinate or ethyl levulinate). The composition can incorporate nicotine and levulinic acid in a salt form (e.g., nicotine levulinate). The composition can be composed of at least two forms of nicotine, and one of the forms of nicotine is in the form of nicotine levulinate. The composition is useful for treatment of central nervous system conditions, diseases, and disorders, and as a nicotine replacement therapy. | 2011-11-03 |
20110268810 | POLYMERIC MATERIALS LOADED WITH MUTAGENIC AND RECOMBINAGENIC NUCLEIC ACIDS - Polymeric microparticles are used to deliver recombinagenic or mutagenic nucleic acid molecules such as donor nucleic acid alone, or in combination with triplex-forming molecules, to induce a site-specific mutation in the target DNA. Target cells endocytose the particles, releasing the nucleic acid molecules inside of the cell, where they induce mutagenesis or recombination at a target site. The examples demonstrate that triplex forming oligonucleotides, preferably PNAs, preferably in combination with a donor nucleotide molecule, can be encapsulated into polymeric microparticles, which are delivered into cells. Results demonstrate significantly greatly levels of uptake and expression, and less cytotoxicity, as compared to direct transfer of the nucleic acid molecules into the cell by nucleofection. | 2011-11-03 |
20110268811 | COMPOSITION AND METHOD TO IMPROVE BLOOD LIPID PROFILES AND OPTIONALLY REDUCE LOW DENSITY LIPOPROTEIN (LDL) PER-OXIDATION IN HUMANS - A composition and method which improves blood lipid profiles and optionally reduces low density lipoprotein (LDL) per-oxidation in humans by administering a therapeutic amount of a composition comprising krill oil in combination with astaxanthin or a mixture of fish oil derived, choline based, phospholipid bound omega-3 fatty acid mixture including phospholipid bound polyunsaturated EPA and DHA. In one embodiment, the krill oil is derived from Euphasia spp., comprising Eicosapentaenoic (EPA) and Docosahexaenoic (DHA) fatty acids in the form of triacylglycerides and phospholipids. The krill oil includes at least 10% EPA and 5% DHA, of which greater than 50% are in the form of phospholipids and the 1-4000 mg of krill oil per daily dose is delivered. | 2011-11-03 |
20110268812 | Cosmetic or dermatological composition comprising the combination of honey and a peptide - A cosmetic composition has a combination of honey or royal jelly, and a peptide, including at least the amino acid sequence Gly-X | 2011-11-03 |
20110268813 | PREVENTING LIVER INJURY AND IMPROVING LIVER FUNCTION EFFECTS OF ENA-ACTIMINERAL RESOURCES - Disclosed is a composition with anti-oxidative, anti-aging and liver-function improvement activities containing ENA actimineral resource A activated water. More specifically, disclosed are a pharmaceutical composition and a health food or health supplement containing, as an active ingredient, an alkaline ENA actimineral resource A activated water prepared from | 2011-11-03 |
20110268814 | USE OF EXTRACTS FROM RABBIT SKIN INFLAMED BY VACCINIA VIRUS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF ACUTE CEREBROVASCULAR DISEASE - The present invention provides a method for treatment of acute cerebrovascular diseases, and also provides the use of the extracts from rabbit skin inflamed by vaccinia virus in the manufacture of a medicament for treatment of acute cerebrovascular diseases. | 2011-11-03 |
20110268815 | TEMPERATURE-INSENSITIVE CALCIUM PHOSPHATE CEMENTS - Temperature-insensitive calcium phosphate cements and methods of using the same are provided. Aspects of the cements include a dry component having fine and coarse calcium phosphate particulate reactants and a setting fluid which includes a cellulose. The dry component and setting fluid may be combined over a broad temperature range to produce a flowable composition. The resultant flowable composition finds use in a variety of different applications, including the repair of hard tissue defects, e.g., bone defects such as fractures. | 2011-11-03 |
20110268816 | APPARATUSES AND SYSTEMS TO PROCESS A FLUID, AND METHODS FOR USING THE SAME - A method for oxygenating a fluid, the method including launching a sub-orbital lower-level apparatus to a predetermined altitude greater than 20,000 feet above sea level. The method also includes, at the predetermined altitude, actuating a fluid capture mechanism sealingly configured to collect and store an atmospheric fluid. In addition, returning the a sub-orbital lower-level apparatus to an altitude less than 20,000 feet, and introducing at least a portion of the atmospheric fluid to an oxygenation process to mix the captured atmospheric fluid with another fluid. | 2011-11-03 |
20110268817 | COMPOUNDS USEFUL FOR THE PREVENTION OR TREATMENT OF ACCOMODATIVE ASTHENOPIA - It is described the use of L-carnitine, in combination with antioxidants such as vitamin E and inorganic elements such as manganese, zinc, sodium and potassium, for the preparation of a physiological supplement or medicament for opthalmic use, for the prevention or treatment of accomodative asthenopia. | 2011-11-03 |
20110268818 | NGAL-BINDING SIDEROPHORES AND USE THEREOF TO TREAT IRON DEFICIENCY AND IRON OVERLOAD - The invention provides compositions comprising a lipocalin, such as NGAL, and a mammalian siderophore that are useful as iron chelators and iron donors. The invention also provides mammalian siderophore compounds of Formula (I): The invention further provides, methods of treatment and methods of diagnosis. | 2011-11-03 |
20110268819 | ANTINFECTIVE FREE INTRAMAMMARY VETERINARY COMPOSITION - An antiinfective-free formulation for prophylactic treatment of mastitis in dry cows comprises a seal formulation having approximately 65% by weight of bismuth sub-nitrate in a gel based on aluminium stearate. The seal formulation is prepared by adding the bismuth sub-nitrate to the gel base in at least two separate stages. | 2011-11-03 |
20110268820 | USE OF SELECTIVE ESTROGEN RECEPTOR MODULATOR FOR JOINT FUSION AND OTHER REPAIR OR HEALING OF CONNECTIVE TISSUE - Methods for facilitating joint immobilization or fusion using selective estrogen receptor modulator (SERM) such as raloxifene are disclosed. The SERM may be administered systemically or locally. In conjunction with SERM, other therapeutic agents such as calcium, vitamin D, bone morphogenetic protein may be administered simultaneously. The method can similarly be applied to facilitate bone repair, bone healing, and connective tissue healing processes in a patient. | 2011-11-03 |
20110268821 | EXTRACTING AN EXTRACT SUBSTANCE FROM A RAW MATERIAL - The present invention relates broadly to the extraction of an extract substance from a raw material. The extract substance may have application in the food, cosmetics, insecticide or other industries. The raw material may be in the form of vegetable or fruit matter or waste. The extract substance is to be in the form of a concentrated food (for humans or animals) or cosmetic including but not limited to aromatic substances. | 2011-11-03 |
20110268822 | METHODS FOR SYNTHESIZING KOTALANOL AND STEREOISOMERS AND ANALOGUES THEREOF, AND NOVEL COMPOUNDS PRODUCED THEREBY - Compounds having the general formula (I): wherein X is S, Se or NH, and stereoisomers thereof, and de-O-sulfonated analogues of all of the foregoing, but excluding naturally occurring kotalanol and de-O-sulfonated kotalanol, and methods for synthesizing same. The compounds are useful as glycosidase inhibitors, and may be used in the treatment of diabetes. The synthetic compounds may also be used as standards in the calibration or grading of natural or herbal remedies produced from natural sources of glycosidase inhibitors such as kotalanol. | 2011-11-03 |
20110268823 | METHOD FOR PREPARING EXTRACT FRACTON REINFORCED WITH GINSENOSIDES RG1 OR RB1 FROM GINSENG - The present invention provides a method for preparing an extract fraction reinforced with ginsenoside Rg1 or Rb1 from | 2011-11-03 |
20110268824 | COMPOSITION FOR PREVENTING OR TREATING ARTHEROSCLEROSIS - A composition according to the present invention is a composition containing extract of | 2011-11-03 |
20110268825 | COMPOSITIONS THAT INCLUDE ANTHOCYANIDINS AND METHODS OF USE - The compositions described herein and featured in the present invention include those that comprise anthocyanidin combinations rich in delphinidins, including delphinidins such as the ones found in berries. The compositions can optionally include either compositions that comprise andrographolides, such as the ones found in a plant of the genus | 2011-11-03 |
20110268826 | GIP-Increase Inhibitor - A GIP-increase inhibitor, which is useful as a drug or a food, comprising a rice bran extract as an active ingredient. | 2011-11-03 |
20110268827 | EYESIGHT-PROTECTING COMPOSITION CONTAINING FUNCTIONAL COMPONENTS HAVING PREVENTIVE AND THERAPEUTIC EFFICACY IN DIABETES OR DIABETES COMPLICATIONS - A vision-protecting composition with prophylactic and therapeutic activity of diabetes or diabetic complications, comprising calcium, vitamin A, vitamin B, vitamin C and vitamin D as functional ingredients, in combination with at least one herb extract selected from the group consisting of a wolfberry extract, an | 2011-11-03 |
20110268828 | CELL RECEPTOR BLOCKER FOR PREVENTING AND TREATING AVIAN INFLUENZA AND OTHER DISEASES CAUSED BY VIRUSES - Use of previously inactivated viral particles of the avian influenza virus or of previously purified antigenic components thereof, alone or in combination with carriers of biological origin in a composition administered via the respiratory system in order to prevent and to treat avian influenza, and also the composition mentioned. The product inhibits the coupling of said pathogenic virus, occupying the cell receptors for viral haemagglutinins. | 2011-11-03 |
20110268829 | QUALITY OF LIFE FOR HEPATITIS C PATIENTS WITH A FORMULATION FOR ADMINISTRATION TO THE ORAL MUCOSA INCLUDING LACTOBACILLUS DELBRUECKII SUBSP. BULGARICUS AND N-ACETYL D-GLUCOSAMINE - Disclosed are quick dissolve tablets, each including | 2011-11-03 |
20110268830 | MICRO-LENS ARRAY FABRICATION APPARATUS - A micro-lens array fabrication apparatus includes a first roller, a second roller, a molding member, and a cooling member. The first roller and the second roller revolve cooperatively to position portions of a substrate on the molding member while maintaining a tension on the substrate. The molding member includes a shaft and two caps connected to opposites ends of the shaft. The shaft defines a through hole and rows of molding holes in a lateral surface thereof, and forms heaters in the though hole. The heaters heat up the substrate till molten, and the air is driven to blow the molten substrate into the molding holes and form a row of micro-lens structures on the currently positioned portion of the substrate. | 2011-11-03 |
20110268831 | Ice cream scoop - An ice cream scoop includes a handle, a scooper coupled to an end of the handle, a scraper installed in the scooper, a link rod extended from an end of the scraper into the end of the handle, and a transmission device installed on the link rod. The ice cream scoop further includes an operating device with an end pivotally coupled to the handle, such that the operating device can be swayed between a first position and a second position with respect to the handle. The operating device further includes a driving portion coupled to the transmission device. If the operating device is swayed between the first and second positions, the link rod will be rotated, and the scraper will be moved along an internal wall of the scooper. | 2011-11-03 |
20110268832 | System and Method for Making Lab Card by Embossing - In one aspect of the invention, systems, methods, and devices are provided for creating microfluidic and nanofluidic structures. In some embodiments, such systems, methods, and devices are used to create features with high aspect ratios in lab cards. | 2011-11-03 |
20110268833 | NONCONFORMING ANTI-SLICE BALL - A non-conforming golf ball has a plurality of dimples formed on the outer surface of the ball in a predetermined dimple pattern, the outer surface comprising one or more first areas which include a plurality of first dimples which together have a first dimple volume and at least one second area having a dimple volume less that the first dimple volume, the first and second areas being configured to establish a preferred spin axis. The second area may be a band around the equator which has a lower dimple volume or no dimples, with the polar regions have a higher volume of dimples, creating a preferred spin axis through the poles. | 2011-11-03 |
20110268834 | INJECTION MOLDING MACHINE WITH OFFSET MOVING PLATEN ACTUATOR - An injection molding machine comprises a first platen and a second platen, the first platen movable relative to the second platen in an axial direction between open and closed positions, and a plurality of tie bars extending generally between the first and second platens for coupling together the first and second platens. At least a first locking device is mounted to the first platen and associated with a first one of the tie bars for selectively locking and unlocking the moving platen relative to the tie bar. At least a first clamping mechanism is mounted to the second platen and associated with the first tie bar, the clamping mechanism including clamp and unclamp chambers on either side of a piston for moving the piston towards clamp and unclamp positions to exert a clamping force and a mold break force, respectively. The machine further includes a traverse actuator comprising one or more linear actuators coupled to at least one of the first and second platens for effecting said movement of the first platen relative to the second platen between the open and closed positions, the one or more linear actuators together being free of provision for applying a mold break force to the platens. | 2011-11-03 |
20110268835 | Sorting System for Cattle - Disclosed herein is a method of sorting, treating, and feeding a group of bovine animals in a feed lot, wherein the method may include the steps of determining an ob genotype of each animal, comparing the relative weight and back fat of each animal with the other animals, dividing the animals into subgroups based on weight, back fat, and ob genotype. Zilpaterol hydrochloride (ZH) may be added to a feed ration fed to animals only in selected subgroups. Each group is fed a finishing period and then moved lot to slaughter. Each slaughter date and finishing period is independent of other subgroups. | 2011-11-03 |